Treatment Patterns and Outcomes Among Patients Who Initiate Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care

被引：0
|
作者：
Romanus, Dorothy [1 ]
Jhaveri, Mehul [1 ]
Labotka, Richard [1 ]
Henk, Henry [2 ]
Seal, Brian [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Optum, HEOR, Eden Prairie, MN USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Characteristics, Treatment Patterns, and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in North America (NA) and Europe: Findings from the PREAMBLE Study
    Vij, Ravi
    Chen, Clara
    Davis, Catherine
    Kim, Hyang
    Durie, Brian
    Cook, Gordon
    Goldschmidt, Hartmut
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S252 - S252
  • [32] Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Abadier, Michael
    Estevam, Jose
    Berg, Deborah
    Fedyk, Eric Robert
    [J]. BLOOD, 2020, 136
  • [33] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    [J]. HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [34] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    [J]. HAEMATOLOGICA, 2016, 101 : 538 - 539
  • [35] Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Ibrahim, Emad
    Vallurupalli, Anusha
    Cull, Elizabeth H.
    Green, Damian J.
    Oliver, Kate
    Longcor, Jarrod
    [J]. BLOOD, 2019, 134
  • [36] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
  • [37] Targeted Therapy Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    [J]. ONCOLOGY-NEW YORK, 2021, 35 (05): : 284 - 287
  • [38] Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
    Le Ray, Emmanuelle
    Jagannath, Sundar
    Palumbo, Antonio
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (01) : 91 - 105
  • [39] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    [J]. HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [40] Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeanenne Joy
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345